SWSharon G. Witonsky

Sharon G. Witonsky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sharon G. Witonsky has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • David S. Lindsay

    VA-MD College of Veterinary Medicine

    5 shared publications
  • Robert M. Gogal

    Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, VA 24061, USA

    3 shared publications
  • Virginia Buechner-Maxwell

    Large Animal Clinical Sciences, Virginia Maryland College of Veterinary Medicine , Blacksburg, Virginia

    3 shared publications
  • Alayna. N. Hay

    Department of Small Animal Clinical Sciences, Virginia Maryland College of Veterinary Medicine, Blacksburg, VA 24061, USA

    2 shared publications
  • Anne Cook

    Virginia-Maryland Regional College of Veterinary Medicine , Blacksburg, VA

    2 shared publications
  • Bettina Wagner

    Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, USA

    2 shared publications

Latest Publications

  • Horses affected by EPM have increased sCD14 compared to healthy horses

    by Alayna N. Hay, Bettina Wagner, Caroline M. Leeth, Tanya LeRoith, Thomas E. Cecere, Kevin K. Lahmers, Frank M. Andrews, Stephen R. Werre, Amy L. Johnson, Carol K. Clark, et al.


  • Open Access

    Engrafting Horse Immune Cells into Mouse Hosts for the Study of the Acute Equine Immune Responses

    by Caroline Leeth, Janie Adkins, Alayna Hay, Sophie Bogers, Ashley Potter, Sharon Witonsky, Jing Zhu

    Immunological studies in the horse are frequently hampered by lack of environmental control, complicated study design, and ethical concerns when performing high risk studies. The purpose of the current study was to investigate the utility of a xenograft model for studying acute equine immune responses. Immunocompromised non obese diabetic (NOD). sudden combined immunodeficiency (scid).gamma-/- (NSG) mice were engrafted with either equine peripheral blood lymphocytes (PBLs) or equine bone marrow to determine an optimal protocol for equine lymphocyte engraftment. We found that both PBL and bone marrow grafts populated the host mice successfully. Bone marrow transplants were technically more challenging and required further processing to retard graft versus host disease. Graft vs host disease was apparent at 28 days post-PBL transfer and 56 days post-bone marrow transfer. The results of these studies support the use of mouse hosts to study acute equine immune responses and that different engraftment techniques can be used depending on the experimental design.


  • Open Access

    Can levamisole upregulate the equine cell-mediated macrophage (M1) dendritic cell (DC1) T-helper 1 (CD4 Th1) T-cytotoxic (CD8) immune response in vitro?

    by Sharon Witonsky, Virginia Buechner-Maxwell, Amy Santonastasto, Robert Pleasant, Stephen Werre, Bettina Wagner, Siobhan Ellison, David Lindsay

    Background Equine protozoal myeloencephalitis (EPM) is a common and devastating neurologic disease of horses in the United States. Because some EPM‐affected horses have decreased immune responses, immunomodulators such as levamisole have been proposed as supplemental treatments. However, little is known about levamisole's effects or its mechanism of action in horses. Objective Levamisole in combination with another mitogen will stimulate a macrophage 1 (M1), dendritic cell 1 (DC1), T‐helper 1 (CD4 Th1), and T‐cytotoxic (CD8) immune response in equine peripheral blood mononuclear cells (PBMCs) in vitro as compared to mitogen alone. Animals Ten neurologically normal adult horses serologically negative for Sarcocystis neurona. Methods Prospective study. Optimal conditions for levamisole were determined based on cellular proliferation. Peripheral blood mononuclear cells were then cultured using optimal conditions of mitogen and levamisole to identify the immune phenotype, based on subset‐specific activation markers, intracellular cytokine production, and cytokine concentrations in cell supernatants. Subset‐specific proliferation was determined using a vital stain. Results Concanavalin A (conA) with levamisole, but not levamisole alone, resulted in a significant decrease (P < .05) in PBMC proliferation compared to conA alone. Levamisole alone did not elicit a specific immune phenotype different than that induced by conA. Conclusion and Clinical Importance Levamisole co‐cultured with conA significantly attenuated the PBMC proliferative response as compared with conA. If the mechanisms by which levamisole modulates the immune phenotype can be further defined, levamisole may have potential use in the treatment of inflammatory diseases.


  • Open Access

    Effects of ExperimentalSarcocystis neurona-Induced Infection on Immunity in an Equine Model

    by S. Rochelle Lewis, Siobhan P. Ellison, John J. Dascanio, David S. Lindsay, Robert M. Gogal, Stephen R. Werre, Naveen Surendran, Meghan E. Breen, Bettina M. Heid, Frank M. Andrews, et al.

    Sarcocystis neuronais the most common cause of Equine Protozoal Myeloencephalitis (EPM), affecting 0.5–1% horses in the United States during their lifetimes. The objective of this study was to evaluate the equine immune responses in an experimentally inducedSarcocystis neuronainfection model. Neurologic parameters were recorded prior to and throughout the 70-day study by blinded investigators. Recombinant SnSAG1 ELISA for serum and CSF were used to confirm and track disease progression. All experimentally infected horses displayed neurologic signs after infection. Neutrophils, monocytes, and lymphocytes from infected horses displayed significantly delayed apoptosis at some time points. Cell proliferation was significantly increased inS. neurona-infected horses when stimulated nonspecifically with PMA/I but significantly decreased when stimulated withS. neuronacompared to controls. Collectively, our results suggest that horses experimentally infected withS. neuronamanifest impaired antigen specific response toS. neurona, which could be a function of altered antigen presentation, lack of antigen recognition, or both.


  • Ability of Brucella abortus rough vaccine strains to elicit DC and innate immunity in lung using a murine respiratory model

    by Naveen Surendran, Kurt Zimmerman, Mohamed N. Seleem, Nammalwar Sriranganathan, Stephen M. Boyle, Elizabeth M. Hiltbold, Heather Lawler, Bettina Heid, Sharon G. Witonsky


  • Horses Experimentally Infected with Sarcocystis neurona Develop Altered Immune Responses In Vitro

    by Sharon G. Witonsky, Siobhan Ellison, Jibing Yang, Robert M. Gogal, Heather Lawler, Yasuhiro Suzuki, Namalwar Sriranganathan, Frank Andrews, Daniel Ward, David S. Lindsay

    Equine protozoal myeloencephalitis (EPM) due to Sarcocystis neurona infection is 1 of the most common neurologic diseases in horses in the United States. The mechanisms by which most horses resist disease, as well as the possible mechanisms by which the immune system may be suppressed in horses that develop EPM, are not known. Therefore, the objectives of this study were to determine whether horses experimentally infected with S. neurona developed suppressed immune responses. Thirteen horses that were negative for S. neurona antibodies in serum and cerebrospinal fluid (CSF) were randomly assigned to control (n = 5) or infected (n = 8) treatment groups. Neurologic exams and cerebrospinal fluid analyses were performed prior to, and following, S. neurona infection. Prior to, and at multiple time points following infection, immune parameters were determined. All 8 S. neurona-infected horses developed clinical signs consistent with EPM, and had S. neurona antibodies in the serum and CSF. Both infected and control horses had increased percentages (P < 0.05) of B cells at 28 days postinfection. Infected horses had significantly decreased (P < 0.05) proliferation responses as measured by thymidine incorporation to nonspecific mitogens phorbol myristate acetate (PMA) and ionomycin (I) as soon as 2 days postinfection.


  • HUMORAL IMMUNITY IS NOT CRITICAL FOR PROTECTION AGAINST EXPERIMENTAL INFECTION WITH SARCOCYSTIS NEURONA IN B-CELL–DEFICIENT MICE

    by Sharon G. Witonsky, Robert B. Duncan Jr., Heather Norton, Dan Ward, Jibing Yang, David S. Lindsay

    Immunodeficient B-cell-deficient mice (mmuMT) were infected with Sarcocystis neurona merozoites to determine the role of B cells and the humoral immune response in protective immunity. As expected, the mice did not seroconvert based on a direct agglutination test. Infected mice did not have significant changes in gross pathology at the time points examined. Histologic changes included mild perivascular and peribronchial infiltrate in the lungs; perivascular infiltrate and mild inflammatory sinusoidal foci in the liver; prominent high endothelial venules in the lymph nodes; and moderate cellular expansion of the periarteriolar sheaths (PALS) in the spleen. Changes resolved by day 60 postinfection. Mice developed significant CD4 and CD8 responses in lymphoid organs, including significant effector (CD45RB(high)) and memory (CD44(high)) CD4 and CD8 responses. Flow cytometry confirmed the lack of B cells. Overall, these data suggest that B cells are not critical to the protective immune response to SN infection.


  • Prevention of meningo/encephalomyelitis due to Sarcocystis neurona infection in mice is mediated by CD8 cells

    by Sharon G. Witonsky, Robert M. Gogal, Robert B. Duncan, Heather Norton, Dan Ward, David S. Lindsay


  • Sarcocystis neurona-Specific Immunoglobulin G in the Serum and Cerebrospinal Fluid of Horses Administered S neurona Vaccine

    by Sharon Witonsky, Jennifer K. Morrow, Clare Leger, John Dascanio, Virginia Buechner-Maxwell, Wally Palmer, Kristen Kline, Anne Cook

    A vaccine against Sarcocystis neurona, which induces equine protozoal myeloencephalitis (EPM), has received conditional licensure in the United States. A major concern is whether the immunoglobulin G (IgG) response elicited by the vaccine will compromise the use of Western blotting (WB) as a diagnostic tool in vaccinated horses with neurologic disease. Our goals were to determine if vaccination (1) causes seroconversion; (2) causes at least a transient increase in S neurona-specific IgG in the cerebrospinal fluid (CSF); and (3) induces an IgG response that can be differentiated from that induced by natural exposure. Horses included in the study (n = 29) were older than 6 months with no evidence of neurologic disease. The presence or absence of anti-S neurona antibodies in the serum of each horse was determined by WB analysis. Seropositive horses had CSF collected and submitted for cytology, CSF index, and WB analysis. The vaccine was administered to all the horses and boostered 3–4 weeks later. On day 14 after the 2nd administration, serum and CSF were collected and analyzed. Eighty-nine percent (8 of 9) of the initial seronegative horses seroconverted after vaccination, of which 57% (4 of 7) had anti-S neurona IgG in their CSF. Eighty percent (16 of 20) of the seropositive horses had an increase in serum S neurona IgG after vaccination. Of the 6 of 20 horses that were initially seropositive/CSF negative, 2 were borderline positive for anti-S neurona IgG in the CSF, 2 tested positive, and 2 were excluded because the CSF sample had been contaminated by blood. There were no WB banding patterns that distinguished samples from horses that seroconverted due to vaccination versus natural exposure. Caution must be used in interpreting WB analysis from neurologic horses that have been recently vaccinated for EPM.